Collecting prostate cancer body marker samples during treatment
Part of Cancer, Kidney & urinary clinical trials.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of prostate cancer (proven by pathology/biopsy).
- You can have any cancer stage, including spread to nearby lymph nodes or other organs.
- Your most recent PSA blood test is 100 or less (or it was lowered below 100 with antibiotics).
- You have not had prior radiation therapy to the pelvis.
- You plan to start radiation therapy or have prostate surgery.
- You must be able to consent and your general health level is not too limited.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This trial collects tumor samples from men with prostate cancer to study the bacteria and other microbes inside the tumor. It aims to learn how these microbes might affect the cancer and treatment.
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
This trial studies prostate cancer cells in the blood (“circulating tumor cells”) while you undergo planned prostate surgery. It may help doctors better understand prostate cancer and how it behaves early, which could guide future treatment decisions.
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.